SCHEMBL4098641

SCHEMBL4098641

O=C(O)CCC(=O)CC(=O)CCC(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 6/20 0.68
KDM2A Q9Y2K7 6/20 0.68
EGLN1 Q9GZT9 5/20 0.68
KDM4E B2RXH2 4/20 0.68
KDM5C P41229 4/20 0.68
KDM6B O15054 2/20 0.68
LMNA P02545 5/20 0.64
ALKBH5 Q6P6C2 1/20 0.64
SUCNR1 Q9BXA5 1/20 0.64
GABRR1 P24046 1/20 0.58
ACE P12821 1/20 0.55
FOLH1 Q04609 1/20 0.50
SLC15A2 Q16348 1/20 0.47
MAPK1 P28482 1/20 0.47
SLC13A3 Q8WWT9 1/20 0.47
OR51E2 Q9H255 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
TSHR P16473 2/20 0.44
NFKB1 P19838 1/20 0.44
PMP22 Q01453 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17024369 0.97 PHF8 (0.65) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL18342669 0.91 PHF8 (0.59) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL218098 0.90 PHF8 (0.65) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL30572348 0.90 PHF8 (0.65) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377429 0.87 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377444 0.87 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377423 0.87 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377438 0.87 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
Ammonia Solution, Strong SCHEMBL20377426 0.87 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL6914036 0.87 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9770442-B2 Self-assembling amphiphilic polymers as anti-cancer agents ALLEXCEL INC. (US) 2017-09-26 US disclosed
US-8968716-B2 In situ-forming hydrogel for tissue adhesives and biomedical use thereof AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2015-03-03 US disclosed
US-8815277-B2 In situ forming hydrogel and biomedical use thereof AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2014-08-26 US disclosed
US-8791211-B2 High refractive polymers, optical elements, and photoelectric device employing the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2014-07-29 US disclosed
US-20130224795-A1 IMMOBILIZATION METHOD OF BIOACTIVE MOLECULES USING POLYPHENOL OXIDASE AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2013-08-29 US disclosed
US-20120197000-A1 HIGH REFRACTIVE POLYMERS, OPTICAL ELEMENTS, AND PHOTOELECTRIC DEVICE EMPLOYING THE SAME INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2012-08-02 US disclosed
US-20120156164-A1 IN SITU-FORMING HYDROGEL FOR TISSUE ADHESIVES AND BIOMEDICAL USE THEREOF AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2012-06-21 US disclosed
US-8173764-B2 Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers ALLEXCEL INC. (US) 2012-05-08 US disclosed
US-20120100103-A1 IN SITU FORMING HYDROGEL AND BIOMEDICAL USE THEREOF AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2012-04-26 US disclosed
US-7960498-B2 Tissue adhesives with modified elasticity ACTAMAX SURGICAL MATERIALS, LLC (US) 2011-06-14 US disclosed
US-20100260743-A1 Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers ALLEXCEL, INC. (US) 2010-10-14 US disclosed
US-20100239659-A1 SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS ALLEXCEL., INC. (US) 2010-09-23 US disclosed
US-20100008938-A1 SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS ALLEXCEL, INC. 2010-01-14 US disclosed
US-20080004421-A1 Tissue adhesives with modified elasticity ACTAMAX SURGICAL MATERIALS, LLC 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100103-A1 IN SITU FORMING HYDROGEL AND BIOMEDICAL USE THEREOF CD44, MYB, PLOD3 PHF8 802/4885KDM2A 2354/4885EGLN1 247/4885
US-20100008938-A1 SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS PICALM, CLTA, HAVCR2 PHF8 2495/4885KDM2A 4084/4885EGLN1 4108/4885
US-20100239659-A1 SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS CD44, EPCAM, EGFR PHF8 2908/4885KDM2A 4561/4885EGLN1 4706/4885
US-20120156164-A1 IN SITU-FORMING HYDROGEL FOR TISSUE ADHESIVES AND BIOMEDICAL USE THEREOF CD44, DBH, TYR PHF8 1273/4885KDM2A 1034/4885EGLN1 1630/4885
US-20100260743-A1 Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers CD44, ABCG2, ABCC1 PHF8 3304/4885KDM2A 4796/4885EGLN1 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.